by Ethan Perlstein | Jun 14, 2018 | Rare Diseases |
I just attended the 2018 Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C (NPC) research. My mind is still spinning from all the productive interactions and conversations I had over three session-packed days at The Westin La Paloma...
by Ethan Perlstein | Dec 6, 2017 | Perlara science |
This is the fourth post in an open science blog series about PERL101 (P101), a small molecule with big hopes. Demystifying drug discovery The default setting of biotech startups and pharma giants alike is stealth mode. At Perlara the default is set to open. As the...
by Feba Sam | Feb 1, 2017 | Perlara science |
I, along with Nina, performed our first high-throughput screen – well really medium-throughput but high-throughput for us – on Niemann-Pick Type C (NPC) patient-derived fibroblasts a couple of months back. We wanted to do a pilot screen with the Microsource bioactives...
by Nina DiPrimio | Jan 12, 2017 | Perlara science |
Well it has been a little while since I wrote a post, and a lot has happened since then, which I am sure you read about in our blogs and tweets. We changed our company name, partnered with Novartis and started partnering with patient groups to engineer our organisms...
by Tom Hartl | Aug 16, 2016 | Science |
Here I’ll sum up a recent paper in Developmental Cell by E. Thomas Danielson and Morten E. Moeller. The paper, entitled “A Drosophila Genome-Wide Screen Identifies Regulators of Steroid Hormone Production and Developmental Timing,” utilized the Vienna Drosophila RNAi...
